AllSci News
Evommune to focus on dermatology after MRGPRX2 antagonist stumbles in Phase IIb CSU trial
Palo Alto-based Evommune, Inc. (NYSE: EVMN) reported that its oral MRGPRX2 antagonist EVO756 failed to meet its primary endpoint in a Phase IIb trial in...
Roche supplies Tecentriq for pairing with Excalipoint’s tri-specific TCE in SCLC
China-based Excalipoint Therapeutics announced a clinical trial collaboration with Roche to evaluate EXP011 (CTM012), its lead tri-specific T-cell engager, in combination with…
Zymeworks acquires Theravance for USD 929m to secure Yupelri's USD 60m annual cash flows
Canada-based Zymeworks Inc. (Nasdaq: ZYME) has agreed to acquire Dublin-based Theravance Biopharma, Inc. (Nasdaq: TBPH) for USD 17.00 per share in cash,...
Talawar's SPAC merger secures USD 285m to advance dual-pathway atopic dermatitis bispecific
New York-based Talawar Therapeutics has announced a definitive business combination agreement with JATT II Acquisition Corp (Nasdaq: JATT), a Cayman...
Sweden's Flerie acquires Biosergen to revive clinical-stage antifungal candidate
Sweden-based Flerie AB (Nasdaq Stockholm: FLERIE) has agreed to acquire Sweden-based Biosergen AB through a statutory merger, valuing Biosergen at...
Ipsen buys Kartos to add Phase III MDM2 inhibitor for myelofibrosis
France-based Ipsen (Euronext: IPN; ADR: IPSEY) has agreed to acquire Kartos Therapeutics, a Redwood City, California-based clinical-stage company, in a...
Siren Bio advances AAV immune-gene therapy into clinical trials for recurrent glioblastoma
San Francisco-based Siren Biotechnology has received a USD 8 million CLIN2 grant from the California Institute for Regenerative Medicine (CIRM) to advance...
Viridian’s Lumvoa becomes first to treat active and chronic thyroid eye disease with single label
Massachusetts-based Viridian Therapeutics (Nasdaq: VRDN) has received US FDA approval for Lumvoa (veligrotug-vvze), a full insulin-like growth factor-1 receptor (IGF-1R) antagonist for…
MSD explores regional pharma hub in Abu Dhabi to serve Gulf markets
The Department of Health – Abu Dhabi (DoH) and Merck & Co., Inc. (MSD) announced a collaboration to explore establishing a regional…
Shionogi taps real-world ALS data to strengthen edaravone’s market position post-approval
Japan-based Shionogi & Co., Ltd. (Tokyo: 4507) announced a continued partnership with the ALS/MND Natural History Consortium to access longitudinal, clinic-based real-world…
FDA Schedules Advisory Committee for Capricor's Deramiocel in Duchenne Muscular Dystrophy
San Diego-based Capricor Therapeutics (Nasdaq: CAPR) has announced that the US FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) will...
FDA issues CRL to Sobi’s NASP over manufacturing failings
Sweden-based Swedish Orphan Biovitrum AB (STO: SOBI) disclosed on June 26, 2026, that the US FDA issued a Complete Response Letter (CRL)…
FDA delays Lantheus’ Ga-68 edotreotide approval over third-party manufacturing deficiencies
Lantheus Holdings said the US FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA) seeking approval of LNTH-2501…
Nippon Shinyaku bets on Elixirgen's full-length dystrophin mRNA
Japan-based Nippon Shinyaku Co., Ltd. has signed an option agreement with Baltimore-based Elixirgen Therapeutics, Inc. granting it the right to acquire...
CHMP June 2026: Trofinetide reversal, avacopan revocation, and 6 new medicines advance toward EU approval
The EMA's Committee for Medicinal Products for Human Use concluded its June 2026 meeting with a series of consequential decisions: a rare reversal of a...
The AllSci Brief
Systematic R&D and deal news. Daily.